Amundi
SYRE icon

Amundi’s Spyre Therapeutics SYRE Stock Holding History

Amundi’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$248K Buy
+2,793
New +$204K ﹤0.01% 1909
2025
Q2 		– Sell
-5
Closed -$70 – 2125
2025
Q1 		$70 Sell
5
-27
-84% -$562 ﹤0.01% 2178
2024
Q4 		$769 Buy
+32
New +$938 ﹤0.01% 2058

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Amundi's SYRE Position: Q2 2026 in Review

Amundi opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 2,793 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #1909 among its holdings. This is a return to the name: Amundi previously reported a position in SYRE as recently as Q1 2025.

Amundi first reported a position in SYRE in Q4 2024 and has held it in 3 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Amundi held 2,793 shares of Spyre Therapeutics worth $248K as of Q2 2026.
  • Spyre Therapeutics was a new Amundi position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1909 holding.
  • Amundi first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.